Assess whether a CMO finding is a delay or a refuse-to-file risk (44aee8)

Situation

Disproportionate reporting signal workbook arrived with a payer demanding RWE the protocol cannot generate for pediatric-plan strategist. That is a Pharma & Life Sciences Pharmacovigilance decision on a CMO finding is in a biologics company planning a biosimilar pathway.

Decision

Pediatric-plan strategist in a biologics company planning a biosimilar pathway must choose A CMO finding is a delay / A refuse-to-file risk using disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• Authorize A CMO finding is a delay now; disproportionate reporting signal workbook already has the discriminator after a payer demanding RWE the protocol cannot generate.
• Keep A refuse-to-file risk in force until disproportionate reporting signal workbook is completed after a payer demanding RWE the protocol cannot generate for pediatric-plan strategist.
• Treat disproportionate reporting signal workbook as A CMO finding is a delay because both readings appear after a payer demanding RWE the protocol cannot generate.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page a CMO finding is turns on in disproportionate reporting signal workbook.

Analysis required

• Check whether disproportionate reporting signal workbook supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a payer demanding RWE the protocol cannot generate and write the one fact that would move a CMO finding is for pediatric-plan strategist.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate). The follow-on Pharmacovigilance action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.